I came back from SynBioBeta earlier this month with a question I could not shake: will Anthropic's Claude make AI-first drug discovery companies obsolete?
9 min read
AI
The Long View: Against the Specialists
Anthropic paid $400 million for an eight-month-old stealth biotech and opened a wet lab. The argument: one generalist model, trained heavily on biology, can do more for drug discovery than every specialist tool in the stack.
